Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | MAOA | P21397 | 1/20 | 0.44 |
| ▸ | MAOB | P27338 | 1/20 | 0.44 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.43 |
| ▸ | FNTA | P49354 | 1/20 | 0.41 |
| ▸ | FNTB | P49356 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | MMP2 | P08253 | 1/20 | 0.39 |
| ▸ | MMP9 | P14780 | 1/20 | 0.39 |
| ▸ | MMP8 | P22894 | 1/20 | 0.39 |
| ▸ | MMP14 | P50281 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.39 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.39 |
| ▸ | UTS2R | Q9UKP6 | 1/20 | 0.39 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.38 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.38 |
| ▸ | PPARG | P37231 | 2/20 | 0.38 |
| ▸ | PPARA | Q07869 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3185372 | 0.88 | AOC3 (0.52) | GAAAOC3 | |
| SCHEMBL8115632 | 0.88 | AOC3 (0.52) | GAAAOC3 | |
| SCHEMBL8113426 | 0.88 | AOC3 (0.52) | GAAAOC3 | |
| SCHEMBL6609411 | 0.86 | GAA (0.49) | GAAMAOAMAOBAOC3FNTA | |
| SCHEMBL6609941 | 0.84 | GAA (0.48) | GAAMAOAMAOBAOC3FNTA | |
| SCHEMBL5145618 | 0.82 | AOC3 (0.38) | GAAAOC3 | |
| SCHEMBL11507121 | 0.82 | FFAR1 (0.46) | GAAMAOAMAOBFNTAFNTB | |
| SCHEMBL9607479 | 0.81 | LMNA (0.48) | GAAMAOAMAOBAOC3FNTA | |
| Ethylene Glycol SCHEMBL11585117 | 0.80 | MAOA (0.58) | MAOAMAOBCA2MMP2MMP9 | |
| SCHEMBL11494950 | 0.79 | GAA (0.47) | GAAAOC3MMP2MMP9UTS2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1556393-B1 | NOVEL CYCLIC PHOSPHATE DIESTERS OF 1,3-PROPANE-1-ARYL DIOLS AND THEIR USE IN PREPARING PRODRUGS | METABASIS THERAPEUTICS INC (US) | 2013-12-25 | — | — | EP | disclosed |
| US-7666855-B2 | 2′-C-methyl nucleoside derivatives | METABASIS THERAPEUTICS, INC. (US) | 2010-02-23 | — | — | US | disclosed |
| US-20090131370-A1 | Novel Nucleoside Derivatives | METABASIS THERAPEUTICS , INC. (US) | 2009-05-21 | — | — | US | disclosed |
| US-20090118223-A1 | Novel 2'-c-methyl and 4'c-methyl nucleoside derivatives | MERCK SHARP & DOHME CORP. | 2009-05-07 | — | — | US | disclosed |
| US-7498320-B2 | Cyclic phosphate diesters of 1,3-propane-1-aryl diols and their use in preparing prodrugs | METABASIS THERAPEUTICS, INC. (US) | 2009-03-03 | — | — | US | disclosed |
| EP-1915053-A2 | NOVEL 2'-C-METHYL AND 4'-C-METHYL NUCLEOSIDE DERIVATIVES | Merck & Co., Inc. (US) | 2008-04-30 | — | — | EP | disclosed |
| EP-1905778-A2 | Novel 2'-C-methyl nucleoside derivatives | Metabasis Therapeutics, Inc. (US) | 2008-04-02 | — | — | EP | disclosed |
| US-20070179114-A1 | Novel 2'-C methyl nucleoside derivatives | METABASIS THERAPEUTICS, INC. (US) | 2007-08-02 | — | — | US | disclosed |
| EP-1781101-A2 | NOVEL NUCLEOSIDE DERIVATIVES | Metabasis Therapeutics, Inc. (US) | 2007-05-09 | — | — | EP | disclosed |
| US-20070042989-A1 | Novel 2'-C-methyl nucleoside derivatives | METABASIS THERAPEUTICS, INC. (US) | 2007-02-22 | — | — | US | disclosed |
| WO-2007022073-A2 | NOVEL 2'-C-METHYL AND 4'-C-METHYL NUCLEOSIDE DERIVATIVES | MERCK & CO., INC. (US) | 2007-02-22 | — | — | WO | disclosed |
| US-20070021388-A1 | Novel cyclic phosphate diesters of 1,3-propane-1-aryl diols and their use in preparing prodrugs | CITIBANK, N.A., AS ADMINISTRATIVE AGENT | 2007-01-25 | — | — | US | disclosed |
| US-7148349-B2 | Cyclic phosphate diesters of 1,3-propane-1-aryl diols and their use in preparing prodrugs | METABASIS THERAPEUTICS, INC. (US) | 2006-12-12 | — | — | US | disclosed |
| EP-1720556-A2 | NOVEL 2'-C-METHYL NUCLEOSIDE DERIVATIVES | Merck & Co., Inc. (US) | 2006-11-15 | — | — | EP | disclosed |
| WO-2006033709-A2 | NOVEL NUCLEOSIDE DERIVATIVES | METABASIS THERAPEUTICS, INC. (US) | 2006-03-30 | — | — | WO | disclosed |
| WO-2005084192-A2 | NOVEL 2’-C-METHYL NUCLEOSIDE DERIVATIVES | MERCK & CO., INC. (US) | 2005-09-15 | — | — | WO | disclosed |
| US-20050182252-A1 | Hepatitis C viral infection; 2'-C-beta-methyl-7-deazaadenosine; trans-4-(aryl)-2-(4-nitrophenoxy)-2-oxo-1,3,2-dioxaphosphorinanes | METABASIS THERAPEUTICS, INC. | 2005-08-18 | — | — | US | disclosed |
| EP-1556393-A2 | NOVEL CYCLIC PHOSPHATE DIESTERS OF 1,3-PROPANE-1-ARYL DIOLS AND THEIR USE IN PREPARING PRODRUGS | Metabasis Therapeutics, Inc. (US) | 2005-07-27 | — | — | EP | disclosed |
| US-20040192651-A1 | Novel cyclic phosphate diesters of 1,3-propane-1-aryl diols and their use in preparing prodrugs | CITIBANK, N.A., AS ADMINISTRATIVE AGENT | 2004-09-30 | — | — | US | disclosed |
| WO-2004041834-A2 | NOVEL CYCLIC PHOSPHATE DIESTERS OF 1,3-PROPANE-1-ARYL DIOLS AND THEIR USE IN PREPARING PRODRUGS | METABASIS THERAPEUTICS, INC. (US) | 2004-05-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090131370-A1 | Novel Nucleoside Derivatives | SLC29A1, SLC29A2, PNP | GAA 457/4885MAOA 2772/4885MAOB 1629/4885 |
| US-20050182252-A1 | Hepatitis C viral infection; 2'-C-beta-methyl-7-deazaadenosine; trans-4-(aryl)-2-(4-nitrophenoxy)-2-oxo-1,3,2-dioxaphosphorinanes | MTAP, NT5C3B, ADAR | GAA 1350/4885MAOA 1030/4885MAOB 946/4885 |
| US-20070042989-A1 | Novel 2'-C-methyl nucleoside derivatives | NSUN2, NT5C3B, MTAP | GAA 2205/4885MAOA 3048/4885MAOB 1469/4885 |
| US-20090118223-A1 | Novel 2'-c-methyl and 4'c-methyl nucleoside derivatives | MTAP, NT5C3B, NSUN2 | GAA 3321/4885MAOA 3730/4885MAOB 2432/4885 |
| US-20040192651-A1 | Novel cyclic phosphate diesters of 1,3-propane-1-aryl diols and their use in preparing prodrugs | PNP, CYP2S1, CYP2F1 | GAA 2634/4885MAOA 2759/4885MAOB 2478/4885 |
| US-20070021388-A1 | Novel cyclic phosphate diesters of 1,3-propane-1-aryl diols and their use in preparing prodrugs | PNP, CYP2S1, TYMP | GAA 2542/4885MAOA 2638/4885MAOB 2277/4885 |
| US-20070179114-A1 | Novel 2'-C methyl nucleoside derivatives | NSUN2, NT5C3B, MTAP | GAA 2609/4885MAOA 3349/4885MAOB 1810/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.